Grifols (NSDQ:GRFS) said this week it won FDA approval for its Fibrin Sealant designed for surgical use in adults.
The company said the newly cleared product is composed of the plasma proteins fibrinogen and human thrombin.
Grifols said that the Fibrin Sealant will be manufactured at its Parts de Vallés facilities in Barcelona, Spain, according to an SEC filing.
Last week, Grifols reported third-quarter sales and earnings growth that missed the consensus forecast
The Spanish healthcare giant posted profits of €153.9 million , or €0.22 per share, on sales of €1.06 billion for the three months ended Sept. 30 (about $179.3 million, 23¢ and $1.23 billion, respectively).